Akanda Corp. Reports $46.8M Net Loss, Going Concern Doubt, and Material Weakness in Internal Controls for 2025
Summary
Akanda Corp. reported a $46.8 million net loss for 2025, including a $44.8 million goodwill impairment, and faces substantial doubt about its ability to continue as a going concern. The company also disclosed a material weakness in internal controls and ongoing Nasdaq delisting risk.
Key Events
-
Massive Net Loss and Goodwill Impairment
The company reported a net loss of $46.8 million for the year ended December 31, 2025, a substantial increase from $4.1 million in 2024. This includes a $44.8 million impairment loss on goodwill, primarily from the First Towers acquisition, indicating a significant write-down of the acquired asset's value.
-
Going Concern Doubt
Both management and the independent auditor expressed substantial doubt about the company's ability to continue as a going concern due to significant operating losses, negative cash flows from operations ($6.7 million in 2025), and an accumulated deficit of over $103 million.
-
Material Weakness in Internal Controls
Management concluded that internal controls over financial reporting were not effective as of December 31, 2025, citing inadequate staffing and supervision within bookkeeping and accounting operations as a material weakness.
-
Ongoing Nasdaq Delisting Risk
The company received a Nasdaq non-compliance notification in May 2026 for failing to file its 2025 annual report on time. While this filing addresses that specific issue, the underlying financial distress could lead to further delisting concerns.
Analysis
Akanda Corp.'s annual report reveals a dire financial situation, with a net loss of $46.8 million for 2025, a significant increase from $4.1 million in 2024. This loss was primarily driven by a $44.8 million impairment of goodwill related to the acquisition of First Towers, indicating a substantial write-down of the acquired asset's value. The company's management and auditor explicitly state substantial doubt about its ability to continue as a going concern due to significant operating losses and cash outflows. Furthermore, management identified a material weakness in internal controls over financial reporting due to inadequate staffing and supervision. The company also faces ongoing Nasdaq delisting risk for late filings, though this report aims to address the specific periodic filing non-compliance. These factors, combined with negative working capital and continuous dilutive financing activities, paint a critical picture of financial distress and operational challenges.
At the time of this filing, AKAN was trading at $13.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.